Phospho-KCNJ3 (S185) Antibody

What is the exact epitope recognized by Phospho-KCNJ3 (S185) antibodies?

Phospho-KCNJ3 (S185) antibodies specifically recognize the phosphorylated serine residue at position 185 of the KCNJ3 protein. The immunogen used for generating these antibodies is typically a synthetic peptide derived from human GIRK1/KIR3.1/KCNJ3 around the phosphorylation site of Ser185, spanning amino acids 151-200 . These antibodies are designed to detect endogenous levels of KIR3.1 protein only when phosphorylated at S185, making them valuable tools for studying the phosphorylation status of this specific residue .

Why is there a significant discrepancy between calculated and observed molecular weights for KCNJ3?

• Post-translational modifications (including phosphorylation)

• Protein glycosylation

• Formation of stable dimers

• Protein-detergent complexes during SDS-PAGE

Researchers should be aware of this discrepancy when performing Western blot analysis and use appropriate positive controls to confirm band identity .

What species reactivity can be expected with commonly available Phospho-KCNJ3 (S185) antibodies?

Most commercially available Phospho-KCNJ3 (S185) antibodies demonstrate cross-reactivity with multiple species. According to product documentation, these antibodies typically react with:

What are the validated applications for Phospho-KCNJ3 (S185) antibodies and their optimal working dilutions?

Phospho-KCNJ3 (S185) antibodies have been validated for multiple applications in molecular and cellular biology research. The table below summarizes recommended dilutions based on application:

These dilutions serve as starting points; optimal working concentrations should be determined empirically for each experimental system .

How should samples be prepared to preserve KCNJ3 phosphorylation at Ser185?

Preserving phosphorylation status is critical when working with phospho-specific antibodies. For KCNJ3 (S185) detection, implement the following protocols:

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all lysis and extraction buffers

• Keep samples cold (4°C) throughout processing

• Use rapid fixation methods for IHC/IF to preserve phospho-epitopes

• Avoid repeated freeze-thaw cycles that can lead to epitope degradation

• For tissue samples, process immediately after collection or use appropriate preservation methods

Proper sample handling is essential as phosphorylation can be rapidly lost due to endogenous phosphatase activity, leading to false-negative results .

What controls should be included when designing experiments with Phospho-KCNJ3 (S185) antibodies?

Rigorous experimental design requires appropriate controls to validate antibody specificity and ensure reliable data interpretation:

• Positive controls: Samples with known KCNJ3 phosphorylation at S185 (e.g., insulin-stimulated RAW264.7 cells)

• Negative controls:

  • Samples treated with lambda phosphatase

  • KCNJ3 knockout/knockdown cells or tissues

• Blocking peptide controls: Co-incubation with the immunizing phosphopeptide to confirm specificity

• Secondary antibody-only controls: To assess background signal

• Total KCNJ3 antibody: To compare phosphorylated vs. total protein levels

The validation images provided by manufacturers often demonstrate the use of phospho-blocking peptides, which significantly reduce signal and confirm antibody specificity .

How can Phospho-KCNJ3 (S185) antibodies be utilized to investigate the role of phosphorylation in channel function?

Investigating the functional consequences of KCNJ3 phosphorylation requires sophisticated experimental approaches:

• Patch-clamp electrophysiology: Compare channel activity in systems with varying S185 phosphorylation states

• Phosphomimetic mutations: Create S185D (phosphomimetic) and S185A (phospho-null) mutants to study functional effects

• Proximity ligation assays: Examine how phosphorylation affects protein-protein interactions

• Subcellular localization studies: Use IF with Phospho-KCNJ3 (S185) antibodies to track localization changes upon phosphorylation

• Co-immunoprecipitation: Determine if phosphorylation alters binding to G proteins or other channel subunits

These approaches provide complementary data on how phosphorylation at S185 modulates channel gating, trafficking, and protein interactions .

What signaling pathways are known to regulate KCNJ3 phosphorylation at Ser185?

Current research suggests several kinase pathways that may be involved in KCNJ3 S185 phosphorylation:

• Insulin signaling pathway: Evidence indicates insulin treatment can induce phosphorylation at S185, as demonstrated in RAW264.7 cells

• PKA signaling: G-protein coupled receptor activation may lead to PKA-mediated phosphorylation

• PKC pathway: May regulate channel activity through direct phosphorylation

Researchers investigating these pathways should consider using pathway-specific activators and inhibitors in combination with Phospho-KCNJ3 (S185) antibody detection to establish causal relationships .

How does KCNJ3 phosphorylation correlate with cancer progression, particularly in breast cancer?

Research indicates potential clinical significance of KCNJ3 in cancer biology:

• Increased expression levels of KCNJ3 have been correlated with lymph node metastases and poor prognosis in breast cancer patients

• The phosphorylation status at S185 may contribute to altered channel function in cancer cells

• Comparative studies between normal and malignant tissues show differential KCNJ3 expression patterns

When investigating these correlations, researchers should consider:

• Combining Phospho-KCNJ3 (S185) antibody with total KCNJ3 detection to determine phosphorylation ratios

• Correlating phosphorylation status with clinical outcomes

• Examining colocalization with other cancer biomarkers

What strategies can improve detection sensitivity when working with Phospho-KCNJ3 (S185) antibodies?

Optimizing signal detection is crucial for studying potentially low-abundance phosphorylated proteins:

• Signal amplification methods:

  • Use biotin-streptavidin systems for IHC/IF

  • Employ enhanced chemiluminescence substrates for Western blot

  • Consider tyramide signal amplification for very low abundance targets

• Sample enrichment techniques:

  • Perform phosphoprotein enrichment using metal oxide affinity chromatography

  • Use immunoprecipitation to concentrate KCNJ3 before detection

  • Consider subcellular fractionation to isolate membrane fractions

• Blocking optimization:

  • Use proper blocking reagents to reduce background (BSA or serum)

  • Include monocyte blockers when working with myeloid cells to prevent non-specific binding

  • Consider FcR blocking to prevent non-specific binding, especially in immune cells

• Incubation conditions:

  • Extend primary antibody incubation times (overnight at 4°C)

  • Optimize incubation temperatures for maximum sensitivity

How can researchers verify the specificity of Phospho-KCNJ3 (S185) signal in their experimental system?

• Phosphatase treatment: Treating duplicate samples with lambda phosphatase should eliminate the phospho-specific signal

• Blocking peptide competition: Co-incubation with the phosphopeptide should abolish specific binding

• Stimulation/inhibition experiments: Treatments known to modulate S185 phosphorylation (e.g., insulin stimulation) should alter signal intensity accordingly

• Correlation between methods: Compare results from multiple detection methods (Western blot, IHC, IF) for consistent findings

• siRNA knockdown: Reduction of total KCNJ3 should result in proportional reduction of phospho-signal

For ultimate validation, researchers might consider using KCNJ3 knockout models or phospho-site mutants (S185A) as negative controls .

What are the best approaches for multiplexing Phospho-KCNJ3 (S185) with other antibodies?

When designing multiplexed experiments:

• Antibody species considerations:

  • Use primary antibodies raised in different host species

  • If using multiple rabbit antibodies, consider sequential staining with complete stripping between rounds

• Fluorophore selection for IF:

  • Choose fluorophores with minimal spectral overlap

  • Match low-expressed antigens with bright fluorophores and high-expressed antigens with dimmer fluorophores

  • Avoid fluorophores with similarity to autofluorescence in your cells of interest

• Control for cross-reactivity:

  • Perform single-staining controls to ensure specificity of each antibody

  • Include appropriate blocking steps between antibody applications

• Sequential detection for IHC:

  • Consider chromogenic multiplexing with different substrates

  • Use spectral unmixing systems for fluorescence applications

Careful panel design substantially improves data quality in multiplexed detection systems .

What are the relative advantages of different detection methods for KCNJ3 phosphorylation studies?

Different detection methods offer complementary information when studying KCNJ3 phosphorylation:

Research by Rezaeian et al. suggests that for KCNJ3 detection in FFPE breast cancer samples, ISH methods were superior to IHC regarding robustness, sensitivity, and specificity .

How should researchers approach the validation of KCNJ3 phosphorylation across different experimental platforms?

A comprehensive validation strategy includes:

• Cross-platform correlation:

  • Compare results between Western blot, IHC, and IF

  • Validate antibody performance across different tissue preparations (frozen vs. FFPE)

• Quantitative assessment:

  • Use appropriate image analysis software for quantification

  • Employ statistical methods to assess correlation between techniques

  • Consider Spearman's rank correlation analysis for method comparison

• Biological validation:

  • Confirm that phosphorylation changes correlate with expected biological effects

  • Use functional assays to validate the significance of observed phosphorylation

A study examining KCNJ3 in breast cancer tissue found significant correlation between ISH and microarray data (rS: 0.861; p<0.001), with IHC showing moderate correlation to both methods .